OPT - Opthea Ltd

OPT - Opthea Ltd

https://opthea.com

Recent News

Powered by Alpha Vantage

Opthea Announces Decision to Discontinue Wet AMD Trials

GlobeNewswire • 5 months, 2 weeks ago • score: 0.07

ShORe Phase 3 topline results accelerated. trial did not meet primary endpoint of mean change in BCVA from baseline to week ...

This Brown & Brown Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - AZEK Co ( NYSE:AZEK ) , Akoya Biosciences ( NASDAQ:AKYA )

Benzinga • 5 months, 3 weeks ago • score: 0.11

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Morgan Stanley analyst Bob Huang downgraded the rating for Brown & Brown, Inc.

Opthea Phase 3 Trial Fails To Meet Primary Endpoint, Faces Financial Uncertainty - Opthea ( NASDAQ:OPT )

Benzinga • 5 months, 3 weeks ago • score: 0.05

COAST trial failed to show a significant BCVA improvement over aflibercept alone. Opthea may owe investors up to $680 million under its Development Funding Agreement. Volatility can create massive trading opportunities-if you know how to capitalize on it.

Opthea Announces COAST Phase 3 Trial Topline Results

GlobeNewswire • 5 months, 3 weeks ago • score: 0.11

COAST Phase 3 trial failed to meet primary endpoint of mean change in BCVA from baseline to week ...

Opthea to Present at Oppenheimer Healthcare Conference - Opthea ( NASDAQ:OPT )

Benzinga • 7 months, 1 week ago • score: 0.17

MELBOURNE, Australia and PRINCETON, N.J., Feb. 07, 2025 ( GLOBE NEWSWIRE ) -- Opthea Limited OPT "Opthea", the "Company" ) ) , a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular ...

Opthea to Present at Oppenheimer Healthcare Conference

GlobeNewswire • 7 months, 1 week ago • score: 0.18

MELBOURNE, Australia and PRINCETON, N.J., Feb. 07, 2025 ( GLOBE NEWSWIRE ) -- Opthea Limited ( ASX/NASDAQ:OPT, "Opthea", the "Company" ) , a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related ...

Opthea to Present at 43rd Annual J.P. Morgan Healthcare Conference - Opthea ( NASDAQ:OPT )

Benzinga • 8 months, 3 weeks ago • score: 0.09

Business update to include masked Phase 3 patient demographics and baseline characteristics Presentation on Wednesday, January 15, 2025, 5:15 PM PT in San Francisco, California

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Opthea Limited, a biotechnology company, develops and markets therapies primarily for eye diseases in Australia. The company is headquartered in South Yarra, Australia.

52W High

$6.30

52W Low

$2.95

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

1.50

Valuation

Attractive

As of 2025-03-31 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

6.73

EV/EBITDA (<8 favorable)

-0.73

EV/Revenue (<3 favorable)

6275.54

P/S (TTM) (<3 favorable)

2512.79

P/B (<3 favorable)

4.31

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

0.00%

Institutions (25–75% balanced)

5.06%

Shares Outstanding

153,906,000

Float

785,981,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-03-31 (Overview)

Revenue (TTM)

208,860

Gross Profit (TTM)

208,860

EPS (TTM)

-2.25

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-571.23%

ROE (TTM) (>15% strong)

-33.83%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

-0.26

Momentum

Value

0.0000

Previous

0.0000

Trend

—

Signal Cross

No cross

As of

Sep. 12, 2025